ResearcherTianjin Medical University Cancer Institute and HospitalNo recent work listed
Hehe Li
Matched on ORCID iD 0000-0002-5568-3975; OpenAlex author ID A5101855489. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2017: 1 paper · 2018: none · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers
Papers 8
- Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreati… Co-author DOI 10.1186/s13578-023-01155-8↗
- A case report of surgical resection treatment for complete remission after chemotherapy for advanced pancreatic cancer. Co-author DOI 10.3389/fonc.2023.1155233↗
- Hyperglycemia Enhances Immunosuppression and Aerobic Glycolysis of Pancreatic Cancer Through Upregulating Bmi1-UPF1-HK2 Pathway. Co-author DOI 10.1016/j.jcmgh.2022.07.008↗
- Hypoxia-induced lncRNA CASC9 enhances glycolysis and the epithelial-mesenchymal transition of pancreatic cancer by a positive feedback loop with AKT/HIF-1α sig… Co-author PMID 33520364↗
- ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. Co-author DOI 10.1016/j.omto.2019.07.005↗
- High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. First author DOI 10.1186/s13046-019-1209-9↗
- Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cel… Co-author DOI 10.1186/s13578-019-0312-0↗
- Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells. Co-author DOI 10.1111/jcmm.13126↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Tao Yin · 6 shared papers, 2017–2023 · strength 0.70
- Paper Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentia… DOI 10.1186/s13578-023-01155-8↗
- Paper Hyperglycemia Enhances Immunosuppression and Aerobic Glycolysis of Pancreatic Cancer Through Upregulating Bmi1-UPF1-HK2… DOI 10.1016/j.jcmgh.2022.07.008↗
- Paper ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. DOI 10.1016/j.omto.2019.07.005↗
- Shihong Wu · 5 shared papers, 2019–2023 · strength 0.63
- Paper Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentia… DOI 10.1186/s13578-023-01155-8↗
- Paper Hyperglycemia Enhances Immunosuppression and Aerobic Glycolysis of Pancreatic Cancer Through Upregulating Bmi1-UPF1-HK2… DOI 10.1016/j.jcmgh.2022.07.008↗
- Paper ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. DOI 10.1016/j.omto.2019.07.005↗
- Heshui Wu · 5 shared papers, 2017–2023 · strength 0.60
- Paper Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentia… DOI 10.1186/s13578-023-01155-8↗
- Paper Hyperglycemia Enhances Immunosuppression and Aerobic Glycolysis of Pancreatic Cancer Through Upregulating Bmi1-UPF1-HK2… DOI 10.1016/j.jcmgh.2022.07.008↗
- Paper High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. DOI 10.1186/s13046-019-1209-9↗
- Zhengle Zhang · 5 shared papers, 2017–2023 · strength 0.58
- Paper Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentia… DOI 10.1186/s13578-023-01155-8↗
- Paper Hypoxia-induced lncRNA CASC9 enhances glycolysis and the epithelial-mesenchymal transition of pancreatic cancer by a po… PMID 33520364↗
- Paper ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. DOI 10.1016/j.omto.2019.07.005↗
- Qingke Duan · 5 shared papers, 2017–2023 · strength 0.55
- Paper Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentia… DOI 10.1186/s13578-023-01155-8↗
- Paper ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. DOI 10.1016/j.omto.2019.07.005↗
- Paper High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. DOI 10.1186/s13046-019-1209-9↗
- Chunyou Wang · 5 shared papers, 2017–2023 · strength 0.55
- Paper Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentia… DOI 10.1186/s13578-023-01155-8↗
- Paper ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. DOI 10.1016/j.omto.2019.07.005↗
- Paper High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. DOI 10.1186/s13046-019-1209-9↗
- Hengqiang Zhao · 3 shared papers, 2017–2019 · strength 0.27
- Paper ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. DOI 10.1016/j.omto.2019.07.005↗
- Paper High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. DOI 10.1186/s13046-019-1209-9↗
- Paper Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells. DOI 10.1111/jcmm.13126↗
- Zhongyan Zhang · 1 shared paper, 2023 · strength 0.26
- Xin Wang · 1 shared paper, 2023 · strength 0.26
- Jiaoshun Chen · 1 shared paper, 2022 · strength 0.15
- Haoxiang Zhang · 1 shared paper, 2022 · strength 0.15
- Zibo Meng · 1 shared paper, 2022 · strength 0.15
- Pei Mei · 1 shared paper, 2021 · strength 0.12
- Zhi‐Gang Tang · 1 shared paper, 2021 · strength 0.12
- Hanjun Li · 1 shared paper, 2021 · strength 0.12
- Jing Tao · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.